MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

Search

Adaptive Biotechnologies Corp

Open

7.23 -5.98

Overview

Share price change

24h

Current

Min

7.12

Max

7.69

Key metrics

By Trading Economics

Income

-1.6M

-34M

Sales

1M

47M

EPS

-0.228

Profit margin

-71.044

Employees

619

EBITDA

-1.8M

-26M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+24.77% upside

Dividends

By Dow Jones

Next Earnings

6 maj 2025

Market Stats

By TradingEconomics

Market Cap

90M

1.3B

Previous open

13.21

Previous close

7.23

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Adaptive Biotechnologies Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 mar 2025, 23:43 UTC

Market Talk

Gold Edges Higher, Supported by Looming U.S. Tariffs -- Market Talk

30 mar 2025, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

30 mar 2025, 23:41 UTC

Market Talk

Nikkei May Fall Amid Concerns About U.S. Tariffs, Borrowing Costs -- Market Talk

30 mar 2025, 23:12 UTC

Earnings

Tsingtao Brewery 2024 Net CNY4.34B Vs. Net CNY4.27B >0168.HK

30 mar 2025, 23:12 UTC

Earnings

Tsingtao Brewery Board Proposes Final Dividend of CNY2.20/Share >0168.HK

30 mar 2025, 23:12 UTC

Earnings

Tsingtao Brewery 2024 Rev CNY32.14B Vs. CNY33.94B >0168.HK

30 mar 2025, 22:30 UTC

Earnings

Great Wall Motor 2024 Net CNY12.69 Vs. Net CNY7.02B >2333.HK

30 mar 2025, 22:30 UTC

Earnings

Great Wall Motor: Higher Overseas Vehicle Sales Among Factors Supporting Results >2333.HK

30 mar 2025, 22:30 UTC

Earnings

Great Wall Motor 2024 Rev CNY202.20B Vs. CNY173.21B >2333.HK

30 mar 2025, 21:44 UTC

Market Talk

Barclays Favors Core Bonds Over Equities as Tariffs Loom -- Market Talk

30 mar 2025, 21:24 UTC

Market Talk

Early Polling Shows Labor's Support Firms Before Australia Vote -- Market Talk

30 mar 2025, 21:23 UTC

Top News

Trump Team Weighs Broader, Higher Tariffs -- WSJ

30 mar 2025, 16:23 UTC

Top News

Tesla's EV Credit Income Is Still Rolling In -- for Now -- Barrons.com

30 mar 2025, 09:30 UTC

Top News

The AI Data-Center Boom Is Coming to America's Heartland -- WSJ

30 mar 2025, 09:30 UTC

Top News

Tariffs on Screws Are Already Hitting Manufacturers -- WSJ

29 mar 2025, 13:00 UTC

Top News

Trump's Trade War Arrives in America's Heartland -- WSJ

29 mar 2025, 11:00 UTC

Top News

Selling Your House This Spring? You Might Need to Cut the Price -- Heard on the Street -- WSJ

29 mar 2025, 09:30 UTC

Top News

The Auto Union Boss Who Went From Trump Foe to Tariff Cheerleader -- WSJ

29 mar 2025, 08:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

29 mar 2025, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

29 mar 2025, 00:00 UTC

Top News

The Drone-Delivery Service Beating Amazon to Your Front Door -- WSJ

28 mar 2025, 23:16 UTC

Acquisitions, Mergers, Takeovers

CoreWeave Debuts: A Big IPO in a Slow Year -- Barrons.com

28 mar 2025, 22:21 UTC

Top News

Inflation, Consumer Fears Fuel Stock Selloff -- WSJ

28 mar 2025, 21:49 UTC

Top News

FCC Investigates Disney for DEI Practices, Chair Says -- 2nd Update

28 mar 2025, 21:28 UTC

Top News

Stocks Fall on Tariff, Consumer Sentiment Fears -- WSJ

28 mar 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28 mar 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 mar 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 mar 2025, 20:40 UTC

Top News

OpenAI's Latest Funding Round Comes With a $20 Billion Catch -- WSJ

28 mar 2025, 20:36 UTC

Top News

Consumers' Mood Sours in March With Gloomier Economic Outlook -- 4th Update

Peer Comparison

Price change

Adaptive Biotechnologies Corp Forecast

Price Target

By TipRanks

24.77% upside

12 Months Forecast

Average 9.57 USD  24.77%

High 12 USD

Low 7 USD

Based on 7 Wall Street analysts offering 12 month price targets forAdaptive Biotechnologies Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

6

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

7.55 / 8.5369Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Weak Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.